Mid-Afternoon Market Update: Commercial Vehicle Group Rises On Earnings Beat; Luminex Shares Slide

Toward the end of trading Tuesday, the Dow traded up 0.60 percent to 25,653.87 while the NASDAQ climbed 0.35 percent to 7,887.22. The S&P also rose, gaining 0.37 percent to 2,860.85.

Leading and Lagging Sectors

Tuesday afternoon, the energy shares climbed 1.11 percent. Meanwhile, top gainers in the sector included Renewable Energy Group, Inc. (NASDAQ: REGI ) up 16 percent, and Hornbeck Offshore Services, Inc. (NYSE: HOS ) up 7 percent.

In trading on Tuesday, consumer staples shares fell 0.60 percent.

Top Headline

Emerson Electric Co. (NYSE: EMR ) reported better-than-expected results for its third quarter.

Earnings came in at $0.88 per share, beating market estimates of $0.86 per share. Sales came in at $4.5 billion, beating estimates of $4.46 billion. Emerson Electric expects FY18 GAAP earnings of $3.30 to $3.40 per share.

Equities Trading UP

Commercial Vehicle Group, Inc. (NASDAQ: CVGI ) shares shot up 22 percent to $8.69 after the company beat Q2 earnings estimates and issued strong 2018 production outlook.

Shares of Mallinckrodt Public Limited Company (NYSE: MNK ) got a boost, shooting up 22 percent to $29.63 after the company reported stronger-than-expected results for its second quarter and raised its FY18 earnings outlook.

On Deck Capital Inc (NYSE: ONDK ) shares were also up, gaining 25 percent to $8.50 after the company posted upbeat Q2 results and raised its FY18 guidance.

Equities Trading DOWN

Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) shares dropped 70 percent to $0.6701 after a data monitoring committee recommended that the company's Phase 3 INOvation-1 study of INOpulse for hypertension should be stopped.

Shares of Gemphire Therapeutics Inc. (NASDAQ: GEMP ) were down 53 percent to $3.45. Gemphire Therapeutics announced the FDA has sought data from a sub-chronic toxicology study to support lifting of the partial clinical hold imposed on its gemcabene with respect to clinical trials of duration over six months. The agency also deemed the end-of-Phase 2 meeting and the subsequent initiation of Phase 3 trials investigating gemcabene in dyslipidemia indications and long-term safety exposure trials needed for registration will not take place until the partial hold is lifted. With the timeline for lifting the six-month clinical hold pushed forward from July 31, 2018 to Sept. 30, 2019, the company amended its loan agreement with SVB for purposes of the requirement to provide cash security to SVB, or prepayment of the loan. Separately, the company also said it amended its agreement with Pfizer over gemcabene it signed in April 2011, extending the date of the agreed deadline for the first commercial sales.

Luminex Corporation (NASDAQ: LMNX ) was down, falling around 26 percent to $25.73 after the company missed Q2 sales estimates and issued Q3 and 2018 guidance near low end of estimates.


In commodity news, oil traded up 0.45 percent to $69.32 while gold traded down 0.04 percent to $1,217.20.

Silver traded up 0.01 percent Tuesday to $15.35, while copper rose 0.62 to $2.7485.


European shares closed higher today. The eurozone's STOXX 600 climbed 0.47 percent, the Spanish Ibex Index rose 0.52 percent, while Italy's FTSE MIB Index gained 1.27 percent. Meanwhile the German DAX climbed 0.40 percent, and the French CAC 40 rose 0.81 percent while U.K. shares rose 0.71 percent.


The Johnson Redbook Retail Sales Index rose 0.9 percent during the first four weeks of July versus June.

Data on consumer credit for June will be released at 3:00 p.m. ET.

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.